Company Description
SWK Holdings Corporation, offers specialty finance and asset management services in the United States.
It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.
This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance.
The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform.
It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009.
SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 1996 |
| IPO Date | Sep 22, 1999 |
| Industry | Asset Management |
| Sector | Financials |
| Employees | 22 |
| CEO | Jody. D Staggs |
Contact Details
Address: 5956 Sherry Lane, Suite 650 Dallas, Texas 75225 United States | |
| Phone | (214) 217-7253 |
| Website | swkhold.com |
Stock Details
| Ticker Symbol | SWKH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001089907 |
| CUSIP Number | 78501P203 |
| ISIN Number | US78501P2039 |
| Employer ID | 77-0435679 |
| SIC Code | 6159 |
Key Executives
| Name | Position |
|---|---|
| Jody. D Staggs | Chief Executive Officer and President |
| David R. Earhart | General Counsel and Secretary |
| John David Tamas | Director of Underwriting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | 8-K | Current Report |
| May 20, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 10-K | Annual Report |